ALX Oncology Holdings EBITDA Margin % Historical Data
The historical data trend for ALX Oncology Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ALX Oncology Holdings's EBITDA Margin %
For the Biotechnology subindustry, ALX Oncology Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's EBITDA Margin % falls into.
ALX Oncology Holdings EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
ALX Oncology Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ALX Oncology Holdings EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your 